New England Biolabs Leads Restriction Enzyme Market
ARLINGTON, Va., Feb. 23 /PRNewswire/ -- A recent survey finds that New England Biolabs is the dominant supplier in the market for restriction enzymes. The growth in genomics research is driving demand for restriction enzymes, which are an essential component of many molecular biology techniques including cloning, genotyping, mutation analysis, and sequencing. For suppliers, the restriction enzyme market is particularly lucrative, as the market continues to grow steadily, while relatively little spending is required for new R&D, process development or marketing. It is also a market where every percentage point of market share growth, or loss, can have a dramatic effect on profitability.
In order to benchmark the market for restriction enzymes,
BioInformatics, LLC (http://www.gene2drug.com) -- an Arlington, VA-based market research and consulting firm -- published its latest report, "The Market for Restriction Enzymes: Cutting Out Your Competition." This report offers the first comprehensive evaluation of all of the key market drivers, and goes beyond the conventional wisdom that price and brand image are the sole factors influencing purchase decisions. The report also presents a detailed brand share analysis based upon usage rates and relative expenditure by market segment and geographic region. |
